Abstract
High clinical development costs coupled with declining drug discovery success
rates have meant that pharmaceutical companies must re-evaluate their drug
development process in order to reduce attrition rates and remain competitive.
Over the next decade biomarkers will change the way in which pharma companies
determine the economic viability of their drug discovery process. The use of
biomarkers to aid the discovery of promising products will create an enhanced
understanding of the clinical development process and help to facilitate the
shift towards ' personalized medicine' . ' Commercial Opportunities from
Biomarkers: Transforming drug discovery, clinical development and molecular
diagnostics' is the latest addition to the drug discovery series, examining
recent developments and applications within the biomarkers field. Using
up-to-date case studies to indicate best practice strategies, this report will
ensure that you are able streamline your R&D process and identify potential
cost savings throughout drug discovery and development. Regulatory changes are
analyzed and recent alliances are examined, enabling you to understand the
role and future of this fast-moving field.
| 
View Cart
